Dendritic cell-AML cell fusion vaccine (Dana Farber/Celgene)

N/A

Report date: 2024/12/11 10:41:53

Base Information

Drug NameDendritic cell-AML cell fusion vaccine (Dana Farber/Celgene)

Drug Alias NameN/A

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesCelgene Corp Dana-Farber Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer Institute

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A